PI3K-AKT-mTOR pathway inhibitors present a promising therapeutic option for patients with mTOR-mutated melanoma; non-synonymous mTOR mutations have been strongly linked to reduced survival in melanoma patients (35). This evidence concerns the gene AKT1 and melanoma.